Investigational personalized cellular therapy tolerated well by patients with advanced mesothelioma, ovarian and pancreatic cancers

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology.

from Latest Science News -- ScienceDaily http://ift.tt/1G0irX6
via